Harmony Biosciences Holdings

Company snapshot

At Harmony Biosciences, we are dedicated to developing and delivering innovative therapies for people living with rare neurological diseases who have unmet medical needs. Rooted in our mission, we focus on three therapeutic areas in the neurosciences: sleep/wake, neurobehavioral, and rare epilepsy disorders. Our commitment to pursue innovative and novel treatments extends beyond clinical endpoints

• 2 approved product(s) across US/EU regulatory metadata.
• 21 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Harmony Biosciences Holdings. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Harmony Biosciences Holdings.

1. Jun 8, 2026 Clinical update

   ZYN2-CL-033 — Phase 3

2. Jun 8, 2026 Clinical update

   HBS-101-CL-312 — Phase 3

3. Jun 8, 2026 Clinical update

   Nutra 1-0602 — Unknown

4. Jun 8, 2026 Clinical update

   Nutra 2-1216 — Unknown

5. Jun 8, 2026 Clinical update

   Pitolisant tablet — Phase 3

View all clinical trial activity →

• What is Harmony Biosciences Holdings?

  Harmony Biosciences is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker HRMY. Primary therapeutic focus areas include Idiopathic Hypersomnia, Prader-Willi Syndrome, Hair Thinning, Prader-Willi syndrome, Fragile X Syndrome (FXS). NovaPha

• Is Harmony Biosciences Holdings publicly traded?

  Yes. Harmony Biosciences Holdings is listed with ticker HRMY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Harmony Biosciences Holdings develop or market?

  We link 14 drug profile(s) where Harmony Biosciences Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/harmony-biosciences-holdings#company-drugs.

• What are the latest developments for Harmony Biosciences Holdings?

  In the last 12 months our linked public records show 21 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Harmony Biosciences Holdings focus on?

  Harmony Biosciences Holdings focuses on Idiopathic Hypersomnia, Prader-Willi Syndrome, Hair Thinning based on our analysis of their pipeline programs and drug development activities.